In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.
by Kate Yandell
The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.
by Kevin McLaughlin
At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors’ molecular characteristics, not to their tissues of origin.
A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non–small cell lung cancer treatment.
by Brad Jones
In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
From the Editor-in-Chief
DNA profiling technologies are providing new ways to detect and monitor cancer.
by William G. Nelson, MD, PhD
Response to immunotherapy may be linked to gut microbiome.
by Chris Palmer
New guidelines account for limited medical resources.
by Cameron Walker
Advocates shared their stories and projects at the AACR Annual Meeting.
National Cancer Institute director Norman “Ned” Sharpless meets with advocates and outlines areas of focus for the agency.
by Marci A. Landsmann
To increase efficacy and combat resistance to checkpoint inhibitors, many clinical trials are centered on combining an immune checkpoint inhibitor with a second drug.
The FDA expands use of durvalumab to non–small cell lung cancer.
A collaborative initiative seeks to improve understanding of cancer outcomes in African-American patients through genomic sequencing.
The Financial Toll of Cancer
donate to the AACR